Head-to-head · WeighScore
Big Easy Weight Loss vs Enhance MD
By GLP-1 ScorecardUpdated
Score comparison
Enhance MD has the higher recorded score — 84.8/100 to 75.3/100.
Enhance MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Enhance MD pairs compounded injections with advertised lab testing and care; its four-week supply and 48-week longer plan require a different budget from calendar-month pricing.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Big Easy Weight Loss | Enhance MD |
|---|---|---|
| WeighScore | 75.3/100 | 84.8/100 |
| Grade | C | B |
| Site position | #58 | #4 |
| Semaglutide | $495 per 12 weeks; pricing also shows $399 starter/$495 regular, with pharmacy-specific options. | $249 every 4 weeks on the shortest Core plan; from $212 per 4-week equivalent on a 48-week billed plan (confirm first-order promotion and charge) |
| Tirzepatide | $599 per 12 weeks on the product page; pricing starts at $469 for a separate pharmacy-specific offer. | $329 every 4 weeks on the shortest Advanced plan; from $280 per 4-week equivalent on a 48-week billed plan (confirm first-order promotion and charge) |
| Coverage | All-states claim; confirm physician eligibility and pharmacy shipping restrictions. | FAQ lists 40 states plus DC, subject to product availability; confirm treatment, clinician and pharmacy for your address |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #58 · C
Strengths
- Publishes package and starter prices for comparison before requesting a pharmacy-specific quote.
- Lists pharmacy shipping restrictions; published turnaround ranges differ.
- Names its partner compounding pharmacies and a Chief Medical Officer
What to consider
- Priced as 10 to 12-week packages rather than a simple monthly fee
- New-patient pricing is promotional and may rise on renewal
Site position #4 · B
Strengths
- Core and Advanced publish separate short- and longer-plan prices with billing periods stated
- Product pages advertise care, coaching, supplies and six-month labs; baseline labs are described in onboarding
- Terms identify independent medical groups and possible pharmacies rather than only a generic provider network
- The FAQ publishes a product-availability state list and a clinical-ineligibility initial-payment refund policy
What to consider
- Four-week billing and a 48-week longer plan are not twelve calendar-month payments
- First-order discounts differ by term; actual debit, dose, quantity and ongoing schedule require confirmation
- An unused-prepaid-balance refund formula and precise refill cancellation cutoff were not established
- Pharmacy lists differ across public documents; the assigned dispenser and prescriber remain unknown
- One disclosed pharmacy has a closed Oklahoma nonresident permit; this limited finding does not establish company closure or the pharmacy assigned to a patient
- Elite combination and microdose benefit claims were not independently established; no branded or oral GLP-1 offer was established in the reviewed menu
Featured provider
Enhance MD
Enhance MD scores 84.8/100 (B). Enhance MD pairs compounded injections with advertised lab testing and care; its four-week supply and 48-week longer plan require a different budget from calendar-month pricing.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.